In the planned randomized, placebo-controlled phase I/II trial, 260 CTB-ACE2 and 260 placebo chewing gums are required to conduct a trial with a total of 40 COVID-19 patients for 4 days of treatment. Here, ACE2 is linked to COVID-19.